|
Dr. Jeffrey L. Sturchio is Vice President, Corporate Responsibility, at Merck & Co., Inc., in Whitehouse Station, New Jersey, where he manages a portfolio of activities including Merck's corporate philanthropy, the Merck Institute for Science Education, the Merck Childhood Asthma Network, global health partnerships (including the Merck MECTIZAN Donation Program), global HIV/AIDS access programs, corporate responsibility reporting and the Merck Archives. He also serves as President of The Merck Company Foundation, a US-based, private charitable foundation established in 1957 by Merck & Co., Inc., which is Merck's chief source of funding support to qualified non-profit, charitable organizations. (In 2007, Merck made cash contributions of $62 million, donations of medicines and vaccines—including the Merck Medical Outreach Program and the MECTIZAN Donation Program—of $605 million, and donations of medicines through the Merck Patient Assistance Program of $161 million.)
Since 2000, Dr. Sturchio has been centrally involved in Merck's participation in the UN/Industry Accelerating Access Initiative to help improve HIV/AIDS care and treatment in the developing world. He is a member of the board of the African Comprehensive HIV/AIDS Partnerships in Botswana and also a member of the private sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria. Dr. Sturchio also serves as Chairman of the Corporate Council on Africa (an organization of nearly 200 U.S. companies representing some 85 per cent of total U.S. private sector investments in Africa).
Dr. Sturchio received an A.B. in history (1973) from Princeton University and a Ph.D. in the history & sociology of science from the University of Pennsylvania (1981). His previous positions include the AT&T Archives, the Beckman Center for the History of Chemistry at the University of Pennsylvania, Rutgers University, and the New Jersey Institute of Technology. He has also been a Postdoctoral Fellow and Senior Fellow at the Smithsonian Institution's National Museum of American History (NMAH). In 2004 he was appointed a Visiting Fellow of LSE Health and Social Care at the London School of Economics and elected a Fellow of the American Association for the Advancement of Science. He joined Merck in June 1989 as the Company's first Corporate Archivist.
His publications include Chemistry in America, 1876-1976: Historical Indicators (Reidel, 1985; paperback edition, 1988), written with A. Thackray, P. T. Carroll, and R. F. Bud; Values & Visions: A Merck Century (Merck & Co., Inc., 1991); "Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation" (with L. Galambos), Business History Review 72 (Summer 1998): 250-278; "Against: Direct to consumer advertising is medicalising normal human experience" (with S. Bonaccorso), British Medical Journal 324 (13 April 2002): 910-911; "Successful public-private partnerships in global health: lessons from the MECTIZAN Donation Program," (with B. Colatrella), in The Economics of Essential Medicines, ed. by B. Granville (London: Royal Institute of International Affairs, 2002); "Partnership for action: the experience of the Accelerating Access Initiative, 2000-04, and lessons learned," in Delivering Essential Medicines, ed. by A. Attaran and B. Granville (London: Royal Institute of International Affairs, 2004); and "Business and global health in an era of globalization: reflections on public/private partnerships as a cultural innovation," in Cultural Politics in a Global Age: Uncertainty, Solidarity and Innovation, ed. by D. Held and H. Moore (Oxford, UK: Oneworld Publications, 2008).
|
